{"organizations": [], "uuid": "146fead6072b16065e41c6a9ab265b6d747836fd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/09/business-wire-tim-clackson-ph-d-named-to-forma-therapeutics-board-of-directors.html", "country": "US", "domain_rank": 767, "title": "Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.178, "site_type": "news", "published": "2018-04-09T16:00:00.000+03:00", "replies_count": 0, "uuid": "146fead6072b16065e41c6a9ab265b6d747836fd"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/09/business-wire-tim-clackson-ph-d-named-to-forma-therapeutics-board-of-directors.html", "ord_in_thread": 0, "title": "Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors", "locations": [], "entities": {"persons": [{"name": "tim clackson", "sentiment": "negative"}, {"name": "takeda", "sentiment": "none"}, {"name": "clackson", "sentiment": "none"}, {"name": "tim", "sentiment": "none"}, {"name": "steve tregay", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "watertown", "sentiment": "none"}], "organizations": [{"name": "research and development", "sentiment": "none"}, {"name": "ariad pharmaceuticals, inc.", "sentiment": "none"}, {"name": "ariad", "sentiment": "none"}, {"name": "board’s research and development committee", "sentiment": "none"}, {"name": "board of directors", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WATERTOWN, Mass.--(BUSINESS WIRE)-- FORMA Therapeutics (FORMA) today announced the appointment of Tim Clackson, Ph.D., former President, Research and Development, ARIAD Pharmaceuticals, Inc. to the company’s Board of Directors. Dr. Clackson will serve as the Chair of the Board’s Research and Development Committee. Dr. Clackson served at ARIAD for 22 years, most recently as Chief Scientific Officer from 2003 and as President of Research and Development from 2010 until the acquisition by Takeda in 2017. Under his leadership, the R&D team moved five internally-discovered oncology programs into clinical development, including two to marketing approval.\n“We are extremely fortunate to have Tim join our Board of Directors, given his exceptional background and distinguished expertise in research and development,” stated Steve Tregay, Ph.D., President and CEO, FORMA. “Tim’s leadership directly contributed to ARIAD’s successful development and approval of Iclusig® and Alunbrig® for oncology, the creation of a robust discovery and early development pipeline, as well as the acquisition of ARIAD by Takeda Oncology.”\n“The FORMA team has developed a diverse pipeline of clinical and preclinical programs with considerable promise,” said Dr. Clackson. “I am pleased to join FORMA’s Board of Directors and look forward to working with the management team to help bring these potential medicines to patients.”\nPrior to joining ARIAD in 1994, Tim was a postdoctoral fellow at Genentech, Inc. He received a B.A. degree in Biochemistry from the University of Oxford and a Ph.D. in Biology from the University of Cambridge.\nAbout FORMA\nFORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, neurodegeneration, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis, and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates providing profound patient benefit.\nFORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with operations in Watertown, MA and Branford, CT. www.formatherapeutics.com\nJoin our conversation on Twitter @FORMAInc .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180409005116/en/\nFor FORMA Therapeutics\nMacDougall Biomedical Communications\nKari Watson or Kara Mazey, +1 781-235-3060\nkwatson@macbiocom.com or kmazey@macbiocom.com\nSource: FORMA Therapeutics", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.formatherapeutics.com&esheet=51779798&newsitemid=20180409005116&lan=en-US&anchor=www.formatherapeutics.com&index=1&md5=c1512d0cca1623a5ab5f7bd246ebeb44", "https://www.businesswire.com/news/home/20180409005116/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fformainc&esheet=51779798&newsitemid=20180409005116&lan=en-US&anchor=%40FORMAInc&index=2&md5=672d8d430a764c023ea05f79bbe9ae54"], "published": "2018-04-09T16:00:00.000+03:00", "crawled": "2018-04-09T17:12:55.021+03:00", "highlightTitle": ""}